Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel with or without GSK1120212 in advanced wild-type BRAF melanoma
2011-002545-35Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of trametinib in melanoma (2 arms), sponsored by University of Oxford. Primary endpoint: Maximum tolerated dose of GSK1120212 in combination with paclitaxel. Started Nov 2011; status: completed.
02
Drugs
trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2011-002545-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002545-35.